Technical Analysis for BVNKF - Bavarian Nordic A/S

Grade Last Price % Change Price Change
grade D 25.25 12.22% 2.7500
BVNKF closed up 12.22 percent on Tuesday, September 10, 2019, on 3.62 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Up
See historical BVNKF trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 12.22%
Wide Bands Range Expansion 12.22%
Gapped Up Strength 12.22%
Oversold Stochastic Weakness 12.22%

Older signals for BVNKF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.
Biotechnology Cancer Clinical Medicine Drugs Life Sciences Infectious Diseases Vaccines Bristol Myers Squibb Cancer Vaccines Hpv Bavarian Nordic Metastatic Cancer Ebola National Cancer Institute Us Department Of Defense Biomedical Advanced Research And Development Authority Company Markets Non Replicating Smallpox Cv301 Ebola Vaccine Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer Prostvac Treatment Multiple Cancers Treatment Of Life Threatening Infectious Diseases Treatment Of Metastatic Cancer
Is BVNKF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 70.86
52 Week Low 19.2
Average Volume 552
200-Day Moving Average 0.0
50-Day Moving Average 39.9985
20-Day Moving Average 28.3828
10-Day Moving Average 23.641
Average True Range 1.9304
ADX 37.44
+DI 39.7194
-DI 59.1664
Chandelier Exit (Long, 3 ATRs ) 34.9451
Chandelier Exit (Short, 3 ATRs ) 24.9912
Upper Bollinger Band 40.6599
Lower Bollinger Band 16.1057
Percent B (%b) 0.37
BandWidth 86.510845
MACD Line -4.8778
MACD Signal Line -5.0468
MACD Histogram 0.169
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.2500
Resistance 3 (R3) 25.2500 25.2500 25.2500
Resistance 2 (R2) 25.2500 25.2500 25.2500 25.2500
Resistance 1 (R1) 25.2500 25.2500 25.2500 25.2500 25.2500
Pivot Point 25.2500 25.2500 25.2500 25.2500 25.2500
Support 1 (S1) 25.2500 25.2500 25.2500 25.2500 25.2500
Support 2 (S2) 25.2500 25.2500 25.2500 25.2500
Support 3 (S3) 25.2500 25.2500 25.2500
Support 4 (S4) 25.2500